PerkinElmer Acquires Cisbio Bioassays from Abénex

Abenex Acquires Cisbio Bioassays from Argos Soditic

June 16, 2016

Biotechnology

French private equity firm Abenex has acquired Cisbio Bioassays from seller Argos Soditic. Abenex will partner with the biotech to support its organic and external growth strategy across pharmaceutical research and in vitro diagnostics; Cisbio has ~210 employees and generates over 85% of revenue outside France.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.

PerkinElmer Acquires Nexcelom Bioscience for $260M

May 13, 2021

Medical Devices

PerkinElmer, Inc. agreed to acquire Nexcelom Bioscience for $260 million in cash, a deal announced in 2021 and completed in June 2021. Nexcelom, a Lawrence, Massachusetts–based maker of automated cell counters, image cytometry systems, consumables and reagents (~130 employees, projected 2021 revenue ~$40M), was owned by its founders and Ampersand Capital Partners.

Bio-Rad Acquires Celsee, Inc.

April 9, 2020

Biotechnology

Bio-Rad Laboratories has acquired Celsee, Inc., a developer of instruments and consumables for single-cell isolation, detection and analysis. The acquisition expands Bio‑Rad’s capabilities in single-cell analysis and precision medicine; terms were not disclosed.

VION Biosciences Acquires BioAssay Systems

February 5, 2025

Biotechnology

VION Biosciences acquired Hayward, California–based BioAssay Systems in January 2025 as the fourth add-on for its life‑science products platform. The deal adds BioAssay Systems’ enzymatic and high‑throughput assay kits, reagents and analytical services to VION’s proprietary product portfolio to accelerate capability expansion for drug discovery and life‑science research customers.